Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older
A Phase 2a, Randomized, Observer-Blind, Placebo Controlled, Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 SARS-COV-2 Vaccine in Adults Aged 18 Years and Older
Sponsor: Biomedical Advanced Research and Development Authority
Listed as NCT04405076, this PHASE2 trial focuses on SARS-CoV-2 and remains completed. Sponsored by Biomedical Advanced Research and Development Authority, it has been updated 13 times since 2020, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Feb 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2021 — Feb 2023 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Oct 2021 — Dec 2021 [monthly]
Active Not Recruiting PHASE2
▶ Show 8 earlier versions
-
Jun 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE2
-
Apr 2021 — Jun 2021 [monthly]
Active Not Recruiting PHASE2
-
Mar 2021 — Apr 2021 [monthly]
Active Not Recruiting PHASE2
-
Feb 2021 — Mar 2021 [monthly]
Active Not Recruiting PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jul 2020 — Aug 2020 [monthly]
Recruiting PHASE2
-
Jun 2020 — Jul 2020 [monthly]
Recruiting PHASE2
First recorded
May 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Biomedical Advanced Research and Development Authority
- ModernaTX, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .